Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 2/2015

01-03-2015 | Original Article

Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma

Authors: Thi-Ngoc Diem Vo, Eiji Mekata, Tomoko Umeda, Hajime Abe, Yuki Kawai, Tsuyoshi Mori, Yoshihiro Kubota, Hisanori Shiomi, Shigeyuki Naka, Tomoharu Shimizu, Satoshi Murata, Hiroshi Yamamoto, Mitsuaki Ishida, Tohru Tani

Published in: Breast Cancer | Issue 2/2015

Login to get access

Abstract

Background

Early diagnosis and treatment for breast cancers has greatly improved in recent years, however, subset of this disease with early recurrence have remained to be unpredictable. Several studies has addressed that strong CD10 expression in tumor stroma is associated with poor survival rate of breast cancers, but no correlation between CD10 expression and disease-free survival has been elucidated yet. For these reasons, this study with modified immunohistochemical (IHC) staining evaluated the expression of CD10 in invasive breast carcinomas (IBCs) and analyzed correlations between CD10 expression on tumor cells, stromal cells and myeloid-like cells with clinicopathological parameters and recurrence status.

Method

IHC staining method was performed on formalin-fixed paraffin-embedded sections of 73 cases of primary IBCs, with record of pathological characteristics of subjects followed up from 1998 to 2007.

Results

Stromal CD10 expression was observed in 39/73 cases (53.4 %) with strong expression in 41.0 %. Three cases stained positive for myeloid-like cells and five for carcinomatous cells, of which 6 cases had recurrence and/or regional LN status. Stromal CD10 expression was significantly higher in the unfavorable group (69.6 %; 16/23 cases) compared with the favorable group (32.1 %; 9/28 cases) (p = 0.048). The levels of CD10 expression showed significant difference among clinical outcomes (recurrence or non-recurrence), independent of regional LN status (p = 0.034), histology type (p = 0.044), ER status (p = 0.042), PgR status (p = 0.039), Her2 status (p = 0.038) and Ki67 index (p = 0.036) (partial Pearson correlations). Cox proportional-hazards regression showed that risk factors for disease-free survival were stromal CD10 expression [CD10±, CD10+ versus CD10++; p = 0.003; HR 2.824 (1.427–5.591)]; regional LN status [N0, N1, N2, versus N3; p = 0.004; HR 2.107 (1.262–3.517)] and PgR status [negative versus positive, p = 0.006, HR 0.172 (0.049–0.596)].

Conclusion

CD10 expression on stroma with or without other positive tumor cells and/or myeloid-like cells may function as a powerful prognostic factor for IBC disease-free survival rates, predicting of potential recurrence. It can be determined by a simple modified IHC staining method, which is independent of other prognostic morphologic markers and biomarkers in IBC.
Literature
1.
Saika K, Sobue T. Epidemiology of breast cancer in Japan and the US. JAMA. 2009;52(1):39–44.
2.
Elston WC, Ellis OI, Pinder ES. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol. 1999;31:209–23.CrossRefPubMed
3.
Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumor stroma in cancer. Nat Rev Cancer. 2004;4:839–49.CrossRefPubMed
4.
Edwards MJ, Bonadonna G, Valagussa P, Gamel JW. End points in the analysis of breast cancer survival: relapse versus death from tumor. Surgery. 1998;124:197–202.CrossRefPubMed
5.
Maguer-Satta V, Besançon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011;29:389–96.CrossRefPubMed
6.
Letarte M, Vera S, Tran R, Addis JB, Onizuka RJ, Quackenbush EJ, et al. Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase. J Exp Med. 1988;168:1247–53.CrossRefPubMed
7.
Shipp MA, Vijayaraghavan J, Schmidt EV, Masteller EL, D’Adamio L, Hersh LB, et al. Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 (‘enkephalinase’): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci. 1989;86:297–301.
8.
Koehn JA, Norman JA, Jones BN, LeSoeur L, Sakane Y, Ghai RD. Degradation of atrial natriuretic factor by kidney cortex membranes. J Biol Chem. 1987;262:11623–7.PubMed
9.
Stephenson SL, Kenny AJ. The hydrolysis of human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J. 1987;243:183–7.PubMedCentralPubMed
10.
Yasuda M, Itoh J, Satoh Y, Kumaki N, Tsukinoki K, Ogane N, Osamura RY. Availability of CD10 as a histopathological diagnostic marker. Acta Histochem Cytochem. 2005;38(1):17–24.CrossRef
11.
Terauchi M, Kajiyama H, Shibata K, Ino K, Mizutani S, Kikkawa F. Anti-progressive effect of neutral endopeptidase 24.11 (NEP/CD10) on cervical carcinoma in vitro and in vivo. Oncology. 2005;69:52–62.CrossRefPubMed
12.
Tokuhara T, Adachi M, Hashida H, Ishida H, Taki T, Higashiyama M, et al. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg. 2001;49:489–96.CrossRefPubMed
13.
Huang WB, Zhou XJ, Chen JY, Zhang LH, Meng K, Ma HH, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn J Clin Oncol. 2005;35:245–50.CrossRefPubMed
14.
Deschamps L, Handra-Luca A, O’Toole D, Sauvanet A, Ruszniewski P, Belghiti J, et al. CD10 expression in pancreatic endocrine tumors: correlation with prognostic factors and survival. Hum Pathol. 2006;37:802–8.CrossRefPubMed
15.
Khanh Do T, Mekata E, Mukaisho K. Prognostic role of CD10+ myeloid cells in association with tumor budding at the invasion front of colorectal cancer. Cancer Sci. 2011;102(9):1724–33.
16.
Fujita S, Taniguchi H, Yao T, Shimoda T, Ueno H, Hirai T, et al. Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression. Int J Colorectal Dis. 2010;25:681–6.CrossRefPubMed
17.
Piattelli A, Fioroni M, Iezzi G, Perrotti V, Stellini E, Piattelli M, et al. CD10 expression in stromal cells of oral cavity squamous cell carcinoma: a clinic and pathologic correlation. Oral Dis. 2006;12:301–4.CrossRefPubMed
18.
Yada K, Kashima K, Daa T, Kitano S, Fujiwara S, Yokoyama S. Expression of CD10 in basal cell carcinoma. Am J Dermatopathol. 2004;26:463–71.CrossRefPubMed
19.
Smollich M, Gotte M, Yip WG, Yong E-S, Kersting C, et al. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat. 2007;106:361–9.CrossRefPubMed
20.
Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch. 2002;440(6):589–93.CrossRefPubMed
21.
Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol. 2007;20(1):84–9.CrossRefPubMed
22.
Kim HS, Kim GY, Kim YW, Park YK, Song JY, Lim SJ. Stromal CD10 expression and relationship to the E-cadherin/b-catenin complex in breast carcinoma. Histopathology. 2010;56:708–19.CrossRefPubMed
23.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.
24.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.
25.
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.CrossRefPubMed
26.
Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486.
27.
Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1992;19:403–10.
28.
Kono S, Sunagawa Y, Higa H, Sunagawa H. Age of menopause in Japanese women: trends and recent changes. Maturitas. 1990;12(1):43–9.CrossRefPubMed
29.
Moritani S, Kushima R, Sugihara H, Bamba M, Kobayashi TK, Hattori T. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol. 2002;15(4):397–405.CrossRefPubMed
30.
Kalof AN, Tam D, Beatty B, Cooper K. Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain. J Clin Pathol. 2004;57(6):625–9.CrossRefPubMedCentralPubMed
31.
Dewar R, Fadare O, Gilmor H, Gown AM. Best practices in diagnostic immunohistochemistry myoepithelial markers in breast pathology. Arch Pathol Lab Med. 2011;135:422–9.PubMed
32.
Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 2001;93(13):979–89.CrossRefPubMed
33.
Salani D, Castro VD, Nicotra MR, Rosano L, Tecce R, Venuti A, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol. 2000;157(5):1537–47.
34.
35.
Witkiewicz AK, Freydin B, Chervoneva I, Potoczek M, Rizzo W, Rui H, et al. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther. 2010;10(4):391–6.CrossRefPubMedCentralPubMed
36.
Pandey PR, Saidou J, Watabe K. Role of myoepithelial cells in breast tumor progression. Front Biosci. 2010;15:226–36.CrossRef
37.
Gusterson BA, Monaghan P, Mahendran R, Ellis J, O’Hare MJ. Identification of myoepithelial cells in human and rat breasts by anti-common acute lymphoblastic leukemia antigen antibody A12. J Natl Cancer Inst. 1986;77:343–9.PubMed
38.
39.
40.
Braham H, Trimeche M, Ziadi S, Mestiri S, Mokni M, Amara K, et al. CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression. Virchows Arch. 2006;449:220–4.CrossRefPubMed
41.
Kondepudi A, Johnson A. Cytokines increase neutral endopeptidase activity in lung fibroblasts. Am Respir Cell Mol Biol. 1993;8:43–9.CrossRef
42.
Humeniuk V, Forrest APM, Hawkins RA, Prescott R. Elastosis and primary breast cancer. Cancer. 1983;52:1448–52.CrossRefPubMed
43.
Rasmussen BB, Pederrsen BV, Thorpe SM, Rose C. Elastosis in relation to prognosis in primary breast carcinoma. Cancer Res. 1985;45:1428–30.PubMed
44.
Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and Her2 in breast cancer. Mod Pathol. 2010;23(suppl 2):S52–59.
45.
Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. 2012;18(4):1004–14.
46.
Desmedt C, Majjaj S, Kheddoumi N, Singhal SK., Haibe-Kains B, El Ouriaghli F, Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. Clin Cancer Res. 2012;18(4).
Metadata
Title
Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma
Authors
Thi-Ngoc Diem Vo
Eiji Mekata
Tomoko Umeda
Hajime Abe
Yuki Kawai
Tsuyoshi Mori
Yoshihiro Kubota
Hisanori Shiomi
Shigeyuki Naka
Tomoharu Shimizu
Satoshi Murata
Hiroshi Yamamoto
Mitsuaki Ishida
Tohru Tani
Publication date
01-03-2015
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2015
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-013-0459-1

Other articles of this Issue 2/2015

Breast Cancer 2/2015 Go to the issue

Original Article

Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study

Original Article

Divisional role of quantitative HER2 testing in breast cancer

Editorial

Z-11 trial and rethinking axillary reverse mapping

Case Report

Malignant lymphoma of the breast in a male patient: ultrasound imaging features

Review Article

HER2-directed therapy: current treatment options for HER2-positive breast cancer

Original Article

Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits